New FDA-Approved Treatment Brings Relief to ATTR-CM Patients
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive heart disease caused by a buildup of a misfolded protein (TTR) in the heart. Over time, this stiffens the heart and leads to symptoms of heart failure (shortness of breath, fatigue, swelling, etc.). Until now, treatment options have been limited. However, the FDA has approved Amvuttra® (vutrisiran) for ATTR-CM in adults, giving new hope to patients, especially older Black Americans who are at high risk of this disease.
Amvuttr...
Amvuttr...